晶华微：新产品批量出货 并购整合实现生态拓展

Group 1 - The core products of Jinghua Micro are widely used in key areas such as healthcare, industrial automation, and smart home, deeply integrating into the digital and intelligent transformation of industries [1] - Jinghua Micro has established stable and close partnerships with well-known companies like Guangdong Leksin Medical Electronics Co., Ltd., Guangdong Xiangshan Weighing Group Co., Ltd., and Unilid Technology (China) Co., Ltd., successfully entering the supply chains of brands like Beierkang and Huashengchang [1] - The global smart home market is projected to grow from $126.1 billion in 2022 to $207.8 billion by 2026, driven by consumer demand for home automation and intelligent living [1] Group 2 - Jinghua Micro has formed mature technical barriers in the smart home sector, successfully integrating into the supply chains of leading brands such as Midea and Supor [1] - The company is accelerating the research and design of a new generation of projects that are more cost-effective and better match customer needs, applicable in areas like lighting control, motor and electromagnetic control, and anti-theft alarms [1] - Shenzhen Chipbond Zhixin Microelectronics Co., Ltd. is a wholly-owned subsidiary acquired by Jinghua Micro in 2024, with new products already in small-scale production for brands like Supor and Aucma [1] Group 3 - Through the acquisition, Jinghua Micro rapidly absorbs core technologies from its subsidiary, integrates R&D resources, and enhances the breadth and depth of its product matrix [2] - The synergy effects post-acquisition are optimizing resource allocation efficiency and enhancing comprehensive service capabilities for downstream customers in consumer electronics and white goods [2] - A brokerage report indicates that Jinghua Micro is expected to create a new growth curve due to its technological advantages from high R&D investment and precise grasp of industry pain points [2] Group 4 - In Q1 2025, Jinghua Micro's total operating revenue reached 37.04 million yuan, a year-on-year increase of 38.70% [4] - The company has continuously strengthened its R&D investment, with the R&D expenditure accounting for 54.12% of its operating revenue in 2024, ranking among the top in the industry [4] - A new product, a blood glucose meter chip with HCT (hematocrit measurement) function, has been successfully shipped in bulk to several well-known domestic brand customers, marking an expansion in the company's market share in the medical electronics field [4]